The DOI matches its Crossref record, with a small difference in title or year; 39 of the 39 references it cites were found in a registry or an index.
Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells
Open accessAbstract
AIM: To analyze interaction of ubiquitin specific peptidase 1 (USP1) with Bcr-Abl and to assess the relation between USP1 functional activity and Bcr-Abl expression in K562 chronic myeloid leukemia cells. MATERIALS AND METHODS: The interaction between USP1 and Bcr-Abl in K562 cells was analyzed by co-immunoprecipitation, Western blot analysis, and confocal microscopy. RESULTS: A direct interaction between Bcr-Abl oncoprotein and USP1 protein in K562 cells was established by co-immunoprecipitation. Immunofluorescence analysis and confocal microscopy revealed that Bcr-Abl/USP1 protein complex is formed in the cell nucleus. The inhibition of USP1 protein activity by ML323 reduced the level of Bcr-Abl oncoprotein in K562 cells. CONCLUSIONS: USP1 protein has been identified as a new protein partner of Bcr-Abl oncoprotein in chronic myeloid leukemia. The relationship between the functional activity of USP1 protein and the level of Bcr-Abl oncoprotein has been demonstrated, suggesting that the targeted inhibition of USP1 activity could be a challenging approach for reducing Bcr-Abl expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These stressed mice also exhibited a higher expression of SASP, CREB, NF-κB, and AP-1 genes.”
From Comprehensive review of chronic stress pathways and the efficacy of behavioral stress reduction programs (BSRPs) in managing diseases. (2024) · cites this paper as [53]
Experimental — accuracy not yet measuredIn the citing paper
“In a study involving male SCID mice subjected to 14 days of restraint stress, researchers observed an increased expression of aging markers such as p16INK4a and p21, alongside reduced DNA damage repair capabilities.”
From Comprehensive review of chronic stress pathways and the efficacy of behavioral stress reduction programs (BSRPs) in managing diseases. (2024) · cites this paper as [53]
In the citing paper
“The findings suggest that chronic stress can significantly affect biological aging pathways, particularly within bone marrow leukocytes, potentially mediated by sympathetic beta-adrenergic receptor activation.”
From Comprehensive review of chronic stress pathways and the efficacy of behavioral stress reduction programs (BSRPs) in managing diseases. (2024) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A practical guide to evaluating colocalization in biological microscopy
Dunn, K. W., Kamocka, M. M., & McDonald, J. H. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00462.2010 · Cited by 2,012
Mechanism and function of deubiquitinating enzymes
Amerik, A. Y., & Hochstrasser, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.10.003 · Cited by 1,010
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás‐Cardama, A., & Cortes, J. E. (2008) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 757
Zinchuk, V. S., Zinchuk, O., & Okada, T. (2007) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.07002 · Cited by 426
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Rossari, F., Minutolo, F., & Orciuolo, E. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0624-2 · Cited by 391
ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity
Colicelli, J. (2010) · Science Signaling · doi:10.1126/scisignal.3139re6 · Cited by 357
Deubiquitinase inhibition as a cancer therapeutic strategy
D’Arcy, P., Wang, X., & Linder, S. T. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.002 · Cited by 328
Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0780-6 · Cited by 225
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s189391 · Cited by 210
García‐Santisteban, I., Peters, G. J., Giovannetti, E., & Rodríguez, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-91 · Cited by 191
Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells
Mistry, H. S., Hsieh, G., Buhrlage, S. J., Huang, M., Park, E., Cuny, G. D., Galinsky, I. A., Stone, R. M., Gray, N. S., D’Andrea, A. D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0103-t · Cited by 169
Statistical tests for measures of colocalization in biological microscopy
MCDONALD, J. H., & DUNN, K. W. (2013) · Journal of Microscopy · doi:10.1111/jmi.12093 · Cited by 140
Deubiquitinases (DUBs) and DUB inhibitors: a patent review
Farshi, P., Deshmukh, R. R., Nwankwo, J. O., Arkwright, R. T., Cvek, B., Liu, J., & Dou, Q. P. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1056737 · Cited by 130
The role of ubiquitination and deubiquitination in the regulation of cell junctions
Cai, J., Culley, M. K., Zhao, Y., & Zhao, J. (2017) · Protein & Cell · doi:10.1007/s13238-017-0486-3 · Cited by 127
USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis
Ma, A., Tang, M., Zhang, L., Wang, B., Yang, Z., Liu, Y., Xu, G., Wu, L., Jing, T., Xu, X., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0590-8 · Cited by 121
The Importance of Ubiquitination and Deubiquitination in Cellular Reprogramming
Suresh, B., Lee, J., Kim, K.-S., & Ramakrishna, S. (2016) · Stem Cells International · doi:10.1155/2016/6705927 · Cited by 114
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis
Sun, H., Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Bartholomeusz, G. A., Talpaz, M., & Donato, N. J. (2011) · Blood · doi:10.1182/blood-2010-03-276477 · Cited by 112
Deubiquitinating enzymes as oncotargets
McClurg, U. L., & Robson, C. N. (2015) · Oncotarget · doi:10.18632/oncotarget.3922 · Cited by 104
Das, D. S., Das, A., Ray, A., Song, Y. Y., Samur, M., Munshi, N. C., Chauhan, D., & Anderson, K. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2692 · Cited by 101
Reckel, S., Hamelin, R., Georgeon, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.36 · Cited by 100
IIIDB: a database for isoform-isoform interactions and isoform network modules
Tseng, Y., Li, W., Chen, C., Zhang, S., Chen, J. J. W., Zhou, X. J., & Liu, C.-C. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s2-s10 · Cited by 80
USP1–UAF1 deubiquitinase complex stabilizes TBK1 and enhances antiviral responses
Yu, Z., Song, H., Jia, M., Zhang, J., Wang, W., Li, Q., Zhang, L., & Zhao, W. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20170180 · Cited by 79
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
Flis, S., & Chojnacki, T. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s191303 · Cited by 74
Xu, X., Li, S., Cui, X., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01406 · Cited by 57
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
Reckel, S., Gehin, C. J. C., Tardivon, D., Georgeon, S., Kükenshöner, T., Löhr, F., Koide, A., Buchner, L., Panjkovich, A., Reynaud, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02313-6 · Cited by 52
Villamil, M. A., Liang, Q., Chen, J., Choi, Y. S., Hou, S., Lee, K. H., & Zhuang, Z. (2012) · Biochemistry · doi:10.1021/bi300845s · Cited by 48
Two Nuclear Localization Signals in USP1 Mediate Nuclear Import of the USP1/UAF1 Complex
García‐Santisteban, I., Zorroza, K., & Rodríguez, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038570 · Cited by 41
Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
Ross, T. S., & Mgbemena, V. E. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.963450 · Cited by 37
Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia
Hai, A., Kizilbash, N., Zaidi, S. H. H., et al. (2014) · Bioinformation · doi:10.6026/97320630010108 · Cited by 36
Miroshnychenko, D., Dubrovska, A., Малюта, С. С., et al. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.11.014 · Cited by 33
Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex
Dexheimer, T. S., Rosenthal, A. S., Qin, L., et al. (2014) · Europe PMC (PubMed Central) · Cited by 29
Olazabal‐Herrero, A., García‐Santisteban, I., & Rodríguez, J. A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0311-7 · Cited by 28
Patel, K., Ahmed, Z. S. O., Huang, X., Yang, Q., Ekinci, E., Neslund-Dudas, C. M., Mitra, B., Elnady, F., Ahn, Y., Yang, H., et al. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0091 · Cited by 25
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation
Zhu, H., & Gao, F. (2019) · Journal of Cancer · doi:10.7150/jca.29528 · Cited by 23
Current perspectives for the treatment of chronic myeloid leukemia
Aladağ, E., & Haznedaroğlu, İ. C. (2019) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1810-81 · Cited by 20
Kapadia, B. B., & Gartenhaus, R. B. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0307 · Cited by 14
Järås, M., Johnels, P., Ågerstam, H., Lassen, C., Rissler, M., Edén, P., Cammenga, J., Olofsson, T., Bjerrum, O. W., Richter, J., et al. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2008.11.003 · Cited by 11
Immunocytochemical study of Bcr and Bcr-Abl localization in K562 cells.
Telegeev, G. D., Dubrovska, A. N., Nadgorna, V. A., et al. (2010) · PubMed · Cited by 9
Self-citationGurianov, D. S., Antonenko, S. V., & Телегеев, Г. Д. (2016) · Biopolymers and Cell · doi:10.7124/bc.000909 · Cited by 9
Self-citation
Research works printed but not linked: 5
- [1]1. Salem А, Loghavi S, Tang G, et al . Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol 2017; 92 : 520-8.
- [6]6. Antonenko S, Gurianov D, Telegeev G. Colocalization of USP1 and РН domain of Bcr-Abl oncoprotein in terms of chronic myeloid leukemia cell rearrangements. Tsitol Genet 2016; 50 : 11-5.
- [20]20. Shibata N, Miyamoto N, Nagai K, et al . Development of protein degradation inducers of oncogenic BCR-ABL pro- - tein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci 2017; 108 : 1657-66.
- [38]38. Gorrepati K, Lupse B, Annamalai K, et al. Loss of deubiquitinase USP1 blocks pancreatic β-cell apoptosis by inhibiting DNA damage response. iScience 2018; 23: 72-86.
- [41]41. Goldbraikh D, Neufeld D, Eid-Mutlak Y, et al. USP1 deubiquitinates protein kinase Akt to inhibit PI3K-AktFoxO signaling in muscle during prolonged starvation. EMBO Rep 2020; 21 : e48791.
Cited by
Sorted by citations
Shchaslyvyi, A. Y., Antonenko, S. V., & Telegeev, G. D. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21081077 · Cited by 73
Self-citation
Metadata
- Authors
- Antonenko, S. V., & Telegeev, G. D.
- Affiliations
- Institute of Molecular Biology and Genetics (UA)
- Venue
- Experimental Oncology
- Published
- 2023-06-01
- Volume
- 42
- Issue
- 2
- Pages
- 109-114
- ISSN
- 0204-3564 (ISSN-L)
- 2312-8852
- 1812-9269
- OpenAlex
- W3038319487
- Cited by
- 19
- References
- 39
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 4
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Experimental Oncology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- USP1, BCR-ABL, chronic myeloid leukemia, K562 cells, protein-protein interaction, nuclear protein complex, targeted therapy
- MeSH terms
- Cell Nucleus, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, K562 Cells, Ubiquitin-Specific Proteases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
